RBC Capital Reports Rating Change and $74 Target On Incyte (NASDAQ:INCY) Jun 27, 2018.

June 27, 2018 - By Jeanette Garcia

Incyte Corporation (NASDAQ:INCY) Corporate Logo

Big Money Sentiment increased to 1.22 in Q1 2018. It has change of 0.16, from 2017Q4’s 1.06. The ratio improved due to Incyte Corporation positioning: 45 sold and 131 reduced. 57 funds bought holdings and 157 increased holdings. Investors holded 191.73 million in 2017Q4 but now own 190.28 million shares or 0.76% less.

State Of Wisconsin Investment Board reported 0.06% in Incyte Corporation (NASDAQ:INCY). Allen Inv Management Limited Liability reported 20,488 shs stake. Atlantic Tru Group Lc has invested 0% in Incyte Corporation (NASDAQ:INCY). Canada Pension Plan Investment Board has invested 0.03% in Incyte Corporation (NASDAQ:INCY). Baystate Wealth Management Ltd Liability Com holds 0% or 20 shs in its capital. Sun Life Inc reported 67 shs or 0% of all its holdings. Cornerstone Advsrs reported 0.05% stake. Dnb Asset Mgmt As stated it has 0% of its capital in Incyte Corporation (NASDAQ:INCY). Peak6 Invests L P holds 0.02% or 68,224 shs in its capital. Obermeyer Wood Invest Counsel Lllp stated it has 6,300 shs or 0.05% of all its holdings. Us Bancshares De invested in 0% or 4,941 shs. Great West Life Assurance Can reported 0.03% of its capital in Incyte Corporation (NASDAQ:INCY). Eagle Asset Management has 0.14% invested in Incyte Corporation (NASDAQ:INCY) for 309,711 shs. Assetmark Inc reported 1,405 shs or 0% of all its holdings. Neuberger Berman Group Inc Lc invested 0.01% in Incyte Corporation (NASDAQ:INCY).

Incyte Corporation had 4 selling transactions and 1 buying transaction since January 5, 2018. This’s net activity of $5.08 million. On Wednesday, May 2 Hoppenot Herve had bought 15,000 shs worth $914,100. SWAIN PAULA J sold $4.99M worth of Incyte Corporation (NASDAQ:INCY) on Monday, April 30. The insider Huber Reid M sold $167,507.

RBC Capital Decreased Incyte (NASDAQ:INCY)’s Rating to “Sector Perform”.

RBC Capital changed on Tuesday, 26 June the rating of Incyte (NASDAQ:INCY). The broker has a $74 TP and downgraded INCY’s stock rating from “Outperform” to “Sector Perform”.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Total analysts of 16 have positions in Incyte (NASDAQ:INCY) as follows: 11 rated it a “Buy”, 0 with “Sell” and 5 with “Hold”. The positive are 69%. Since January 2, 2018 according to StockzIntelligence Inc Incyte has 23 analyst reports. On Thursday, February 15 the rating was maintained by BMO Capital Markets with “Buy”. On Thursday, April 5 Barclays Capital maintained the shares of INCY in report with “Overweight” rating. On Tuesday, June 26 the firm has “Hold” rating by RBC Capital Markets given. The company rating was maintained by BMO Capital Markets on Tuesday, January 2. On Tuesday, May 1 the firm has “Hold” rating given by Oppenheimer. On Thursday, February 15 RBC Capital Markets maintained the shares of INCY in report with “Buy” rating. On Monday, April 9 the firm has “Overweight” rating given by JP Morgan. The stock rating was maintained by Piper Jaffray with “Buy” on Friday, June 15. On Thursday, April 12 the stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given by UBS. On Wednesday, May 30 the rating was initiated by Piper Jaffray with “Buy”.

Ticker’s shares touched $66.43 during the last trading session after 0.45% change.Currently Incyte Corporation is downtrending after 50.56% change in last June 27, 2017. INCY has also 574,982 shares volume. INCY underperformed the S&P 500 by 63.13%.

Incyte Corporation (NASDAQ:INCY)’s earnings release is expected by WallStreet on August, 7, according to Zacks. Analysts have anticipation on stock’s EPS of $-0.06. That’s 0.00 % from last year’s $-0.06 EPS. Analysts at Wall Street see Incyte Corporation’s -66.67 % EPS growth compared to $-0.18 EPS for last quarter.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States.The firm is valued at $14.08 billion. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.Currently it has negative earnings. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases ; and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs.

For more Incyte Corporation (NASDAQ:INCY) news brought out recently go to: 247Wallst.com, Benzinga.com, Benzinga.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Tuesday’s Biggest Winners and Losers in the S&P 500” brought out on June 26, 2018, “Benzinga’s Top Upgrades, Downgrades For June 26, 2018” on June 26, 2018, “Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility” with a publish date: June 26, 2018, “40 Stocks Moving In Tuesday’s Mid-Day Session” and the last “Incyte’s Jakafi successful in mid-stage study in severe form of GvHD” with publication date: June 21, 2018.

Incyte Corporation (NASDAQ:INCY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.